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ABSTRACT 
The endothelium holds a pivotal role in cardiovascular health and disease. Assessment 
of its function was until recently limited to experimental designs due to its location. The 
advent of novel techniques has facilitated testing on a more detailed basis, with focus on 
distinct pathways. This review presents available in-vivo and ex-vivo methods for 
evaluating endothelial function with special focus on more recent ones. The diagnostic 
modalities covered include assessment of epicardial and microvascular coronary endo-
thelial function, local vasodilation by venous occlusion plethysmography and flow-
mediated dilatation, arterial pulse wave analysis and pulse amplitude tonometry, mi-
crovascular blood flow by laser Doppler flowmetry, biochemical markers and bioas-
says, measurement of endothelial-derived microparticles and progenitor cells, and gly-
cocalyx measurements. Insights and practical information on the theoretical basis, 
methodological aspects, and clinical application in various disease states are discussed. 
The ability of these methods to detect endothelial dysfunction before overt cardiovascu-
lar disease manifests make them attractive clinical tools for prevention and rehabilita-
tion.  
 
Keywords: biomarkers; cell-derived microparticles; coronary angiography; endothe-
lium; glycocalyx; nitric oxide; plethysmography; progenitor cells; pulse; laser-doppler 
flowmetry 
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Endothelial function: key biochemical concepts  
The endothelium actively regulates basal vascular tone and reactivity under both 
physiological and pathological conditions; its activity extends far beyond the control of 
vascular tone and vasomotion. In addition, a functional endothelium is a major regulator 
of vascular inflammation and remodelling. An intact endothelial layer is critical for pre-
venting circulating blood cells from exposure to prothrombotic subendothelial matrix 
and inhibits arterial thrombus formation by limiting platelet activation, adhesion, and 
aggregation. In the presence of cardiovascular risk factors, an excessive production of 
superoxide (O2) occurs rapidly, inactivating nitric oxide (NO). Loss of NO bioavail-
ability precedes the development of overt atherosclerosis and is an independent predic-
tor of adverse cardiovascular events. Efforts have been made at translating this knowl-
edge into clinical applications by developing methods for assessing endothelial function 
in coronary arteries. Subsequently, these applications have been expanded to other vas-
cular territories.  
 
Coronary endothelial function  
Despite its invasive nature, angiography remains a broadly used technique for as-
sessing endothelial function of epicardial coronary arteries owing to its availability in 
clinical routine. Pharmacological stimuli to assess epicardial coronary vasodilation in-
clude intracoronary infusion of acetylcholine (ACh), metacholine, or papaverine. ACh 
has been widely used due to the short duration of its effect and favourable safety fea-
tures. It typically causes paradoxical vasoconstriction, as opposed to dilatation, in endo-
thelium-denuded arteries in vitro as well as in atherosclerotic coronary arteries in vivo, 
in part due to impaired muscarinic cholinergic vasodilation in coronary atherosclero-
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sis.1,2 Adenosine is an endothelium-independent vasodilator primarily of the microcir-
culation. It therefore induces an increase in blood flow, which can be used to assess 
flow-mediated vasodilatation. Nitroglycerin has been routinely used to assess endothe-
lium-independent vasodilation owing to direct relaxation of vascular smooth muscle 
cells. It is important to administer intracoronary vasodilator agents as infusions of in-
creasing concentrations to assess dose-response effects.  
 
Methodology  
For epicardial coronary vessels, quantitative coronary angiography (QCA) measures 
changes in their diameter. Changes are usually compared with baseline conditions and 
with vasodilation induced by endotheliumindependent drugs. More recently, non-
invasive QCA has been developed by using computed tomography imaging3 or mag-
netic resonance imaging (MRI).4 In the microvasculature, changes in coronary blood 
flow are assessed by vessel diameter and Doppler flow velocities (online supplemental 
material and Supplemental Figure 1).5 Given the invasive nature of the technique, pa-
tients should be selected carefully. As an example, patients presenting with left main 
coronary artery stenosis should not be considered for this procedure. Non-invasive 
methods, such as MRI and positron emission tomography (PET), for assessment of 
coronary microvascular function have shown impressive improvements. MRI allows an 
accurate quantification of myocardial function, infarct size, and microvascular function. 
PET imaging is a method of choice for myocardial blow flow measurement. Combined 
with pharmacological or physiological endotheliumdependent stimuli (e.g. cold pressor 
testing), it is very valuable in assessing microvascular coronary endothelial function.6 
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An additional method that holds great promise for non-invasive assessment of mi-
crovascular function is thermodilution.7,8  
 
Clinical applications  
Epicardial and microvascular coronary endothelial dysfunction is an independent 
predictor of acute cardiovascular events irrespective of presence or absence of an-
giographically detectable coronary lesions.9,10 Assessment of coronary endothelial func-
tion is particularly important in cardiac transplant recipients because the endothelium is 
an early target of ischaemic, immunological, and pharmacological graft injury, includ-
ing ciclosporin-related vasculopathy. In addition, the concentric nature (intimal thicken-
ing) and diffuse distribution of graft coronary artery lesions may hamper their early de-
tection by angiography. Both epicardial and microvascular endothelium-dependent 
vasomotor dysfunction has been shown to correlate with the development of graft 
atherosclerosis in transplanted patients.11  
 
Venous occlusion plethysmography  
Venous occlusion plethysmography (VOP), established more than 100 years ago, is 
the longest living method for investigating blood flow in humans.12  
 
Methodology  
The main principle of VOP is based on the measurement of tissue (usually muscu-
lar) blood flow by the assessment of the tissue volume change, which is induced by the 
inflation of a cuff proximally to the under evaluation tissue. The cuff is inflated up to 
that pressure which occludes venous outflow (return) but allows arterial inflow. The rate 
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of the volume change is therefore proportional to the rate of arterial inflow. She most 
widely applied method of VOP is based on the use of automatically calibrated mercury-
in-silastic strain gauges,13,14 which are placed as rings around the under examination 
limb. A minimally invasive, modified strain-gauge VOP method is being applied in the 
forearm since the early 1990s in order to investigate in vivo the endothelial function in 
the human microcirculation. This technique requires brachial artery cannulation for in-
tra-arterial infusion of endothelial agonists (mainlyACh or metacholine, bradykinin, 
etc.), which act via specific receptors and induceNOproduction fromendothelial cells. 
Endothelial agonists are infused in escalating doses that induce local vasodilation with-
out systemic haemodynamic effects.15,16 Endothelial function is estimated by the dose–
esponse of the forearm blood flow (FBF, ml/min/100ml tissue) due to the local endothe-
lium-dependent vasodilation. Subsequent intra-arterial infusion of direct smooth muscle 
relaxing factors (e.g. nitrates) is used in order to evaluate the effect of endothelium-
independent vasodilation on FBF. Ideally, simultaneous recordings of FBF at the con-
tralateral arm are required in order to verify the absence of any systemic haemodynamic 
effects, induced by the intra-arterial drug infusion. Strain-gauge VOP is a highly repro-
ducible method that provides valid results with the investigation of a relatively limited 
sample size. Moreover, due to its invasive nature, it permits the local infusion of sub-
stances enabling the investigation of endothelial function. Therefore it is an excellent 
research tool. On the other hand, the main disadvantage of the FBF technique is its very 
same invasive nature, which limits its application in clinical practice.  
 
Clinical applications 
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A very large body of evidence documented the presence of impaired endothelium-
dependent relaxation (low ACh-induced FBF, ACh-FBF) microcirculation in patients 
with cardiovascular risk factors.15,16 Moreover, prospective studies have shown that en-
dothelial dysfunction, as assessed by ACh-FBF, is an independent predictor of cardio-
vascular events in subjects with essential hypertension17 and coronary artery disease.18,19  
 
Flow-mediated dilatation 
Conduit vessels respond to alterations in blood flow by increasing vessel diameter 
via an endothelial dependent mechanism.20,21 The flow-mediated dilatation (FMD) 
technique measures changes in conduit artery diameter by ultrasound. This response has 
been shown to reflect local bioactivity of endothelial-derived NO.22  
 
Methodology 
The brachial artery is most often imaged (online Supplemental Figure 2). FMD stud-
ies are performed in a quiet temperature controlled room while subjects are lying supine 
for >10 min prior to image acquisition. A straight, non-branching segment of the bra-
chial artery above the antecubital fossa is imaged in the longitudinal plane with the ul-
trasound probe securely fixed using a stereotactic clamp. This permits fine adjustments 
in the coronal and sagittal planes. A blood pressure cuff is placed 1-2 cm below the an-
tecubital fossa and inflated to supra-systolic pressure. 23 After cuff release, reactive hy-
peraemia results and is quantified using Doppler. The arterial diameter is recorded at 
end diastole using electrocardiographic gating during image acquisition, to determine 
the response of the conduit artery to increase in flow.24 Changes in the arterial diameter 
are assessed using commercial digital edge detection software. Flow-mediated dilatation 
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is expressed as a percentage change of the arterial diameter from the baseline vessel 
size. Phantom studies have demonstrated that differences in absolute diameter of as lit-
tle as 0.04mm can be detected and differences in artery diameter of 0.1mm can be relia-
bly distinguished.25 Inter- and intraobserver variability studies and assessment of change 
in FMD over time have enabled construction of power curves for different clinical trial 
protocols.26 Well-trained operators are essential to obtain such accurate, reproducible 
measurements.  
 
Clinical applications 
FMD has been shown to be impaired in response to a range of classical and novel 
risk factors from the first decade of life and to decline in proportion to risk factor bur-
den.27 In addition, it was shown that impaired endothelial function is associated with 
more rapid progression of a measure of structural arterial disease, carotid intima media 
thickness in an asymptomatic middleaged population.28 Several studies have shown a 
relationship between endothelial dysfunction and clinical events in high-risk cohorts.9,29 
FMD changes rapidly and can be restored by beneficial lifestyle changes30 and medical 
therapy such as statin use.31  
 
Pulse wave analysis  
The arterial waveform contains important information about the stiffness of the 
large arteries and amount of wave reflection within the arterial system.32 Wave reflec-
tion occurs at sites of impedance mismatch, often branch points, and is usually quanti-
fied by determining the augmentation index (AIx), which represents the difference be-
tween the first and second systolic peaks.33 Although the impedance of the large, elastic 
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arteries is relatively static, impedance of the small arteries and arterioles is much more 
dynamic and depends to a large extent on smooth muscle tone and vessel size. Thus, 
changes in small artery tone affect wave reflection: vasodilatation reduces AIx, whereas 
vasoconstriction increases it.33 One of the main factors regulating vascular tone is endo-
thelium-derived NO, and it is now clear that, through this mechanism, NO also influ-
ences wave reflection and, therefore, the shape of the arterial wave. Glyceryl trinitrate 
(GTN), an NO donor, reduces wave reflection at low doses before any measurable ef-
fect on resistance or mean pressure,34 suggesting that small arteries are more sensitive to 
GTN than resistance vessels. Conversely, inhibiting endogenous NO production with 
LG-monomethyl L-arginine increases wave reflection.35 Klemsdal et al.36 demonstrated 
that ACh, an endothelium-dependent nitrovasodilator, reduces wave reflection in rabbits 
and that this effect is attenuated in hypercholesterolaemic animals with endothelial dys-
function. This important observation led Chowienczyk et al.37 to propose that endothe-
lial function could be assessed in humans by recording the shape of the arterial wave-
form and administering GTN as an endothelium-independent stimulus and the endothe-
lium-dependent agonist salbutamol. Since both drugs could be given non-invasively – 
sublingual and inhaled, respectively – this meant a truly non-invasive method for as-
sessing endothelial function. Subsequent work confirmed the endotheliumdependent na-
ture of salbutamol’s effect on AIx and that the technique was repeatable and correlated 
with more established methodologies.38  
 
Methodology 
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A number of versions have been described, but all rely on non-invasive waveform re-
cording, and administration of GTN and a b2 agonist. Details on the procedure can be 
found in online supplemental material and Supplemental Figure 3.  
 
Clinical applications 
Given the novelty of the technique, relatively few clinical studies have employed 
pulse wave analysis (PWA) to assess endothelial function. However, impaired endothe-
lium-dependent responses have been observed in conditions traditionally associated 
with endothelial dysfunction, including diabetes,37 hypercholesterolaemia, 38 coronary 
artery disease,39 peripheral vascular disease,40 and rheumatoid arthritis.41 The GTN re-
sponse is usually preserved. An inverse correlation between terbutaline response and 
Framingham risk score has been reported,42 along with a stronger correlation between 
individual risk factors and endothelial function assessed with PWA compared to FMD. 
At present there are no data relating the PWA technique to treatment effects or outcome.  
 
 
Peripheral arterial tonometry 
Measurement of peripheral vasodilator response with fingertip peripheral arterial 
tonometry (PAT) technology (EndoPAT; ItamarMedical, Caesarea, Israel) is emerging 
as a useful method for assessing vascular function.43 Although PAT signal is modulated 
by various local, systemic, and environmental factors, this parameter is also affected by 
the bioavailability of NO and, therefore, also depends on endothelial function.44 In re-
sponse to hyperaemic flow, digital pulse amplitude (and hence PATsignal amplitude) 
increases, a response that has been shown to depend in part on NO synthesis.45  
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Methodology 
The EndoPAT device consists of two finger-mounted probes, which include a system 
of inflatable neoprene membranes within a rigid external case. A blood pressure cuff is 
placed on one upper arm (study arm), while the contralateral arm serves as a control 
(control arm). The EndoScore is calculated as the ratio of the average amplitude of the 
PAT signal over a 1-min time interval starting 1.5 min after cuff deflation divided by 
the average amplitude of the PAT signal of a 3.5-min time period before cuff inflation 
(baseline) (Figure 1).46 Augmentation index is also automatically calculated as an aver-
age from multiple pulses using the formula (P2-P1)/P1 (%) where P1 is the peak pres-
sure of the recorded pulse wave and P2 is the pressure of the inflection point corre-
sponding to the arrival of the reflected waves.  
 
Clinical applications 
Digital reactive hyperaemia, as measured by EndoScore, is attenuated in patients with 
coronary endothelial dysfunction, suggesting a role as a non-invasive tool to identify pa-
tients during the early stage of CAD.46 The EndoScore was reduced in subjects with im-
paired endothelial function represented by low FMD and was higher in subjects with 
greater brachial artery FMD responses consistent with more preserved endothelial func-
tion.43 The EndoScore was more impaired in subjects with exercise myocardial perfu-
sion imaging studies that were indicative of coronary artery disease.43 In participants of 
the Framingham Heart Study, obesity and diabetes mellitus, along with the associated 
dyslipidaemia and insulin resistance, have been linked to impaired vasodilator re-
sponses.47,48 Measurements of the PAT index in healthy male adults demonstrated sig-
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nificantly increased responses after the ingestion of a high-flavanol cocoa drink as com-
pared with after a low-flavanol cocoa drink.49 Regarding the incremental value of PAT, 
patients at low Framingham Risk Score risk but with endothelial dysfunction are at a 
higher actual risk than patients with high Framingham Risk Score but normal endothe-
lial function. Furthermore, endothelial dysfunction was found to be an independent risk 
factor for a future major adverse cardiovascular event.50 Research work is lacking for 
the evaluation of the potential role of EndoScore in risk stratification for individuals. 
Data on circadian variation, changes after meals and during concurrent illnesses, or after 
cardioactive medication, blood pressure lowering and/or lipid lowering interventions are 
also missing.  
 
Laser Doppler flowmetry 
Laser Doppler flowmetry (LDF) is a technique enabling the monitoring of skin mi-
crovascular blood flow.51 The assumption is that the response observed in the cutaneous 
circulation is a window towards the responses that should be observed in other vascular 
beds.52  
 
Methodology 
During LDF, the original beam of coherent light changes in contact with moving tis-
sues (red blood cells) and a photodiode measures the emerged beam. The fraction of 
shifted light depends on the concentration of moving red blood cells, whereas the mag-
nitude of the frequency broadening depends on their average velocity.53 Many tech-
niques can be associated to LDF to estimate endothelial function among which direct 
delivery of ACh through iontophoresis or micro-dialysis (Figure 2). Other techniques 
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can also be used such as post-occlusive hyperaemia or local skin heating. The major ad-
vantages are that LDF measures skin blood flow in a non-invasive manner and the di-
rect delivery of ACh to the tissues. The response is monitored non-invasively when us-
ing iontophoresis or with the minimally invasive micro-dialysis technique. Microdialy-
sis requires that a small micro-porous catheter is inserted under the epidermal surface. 
Iontophoresis, the migration of charged substances through the skin by means of small 
continuous galvanic current, allows very small amounts of drugs to be administered 
non-invasively and safely to a localized area.54 The ACh induced vasodilatation during 
iontophoresis is biphasic and involves prostanoid participation.55 Various other drugs 
(adrenaline, insuline, sodium nitroprusside, etc.) can be used to test different pathways. 
These have almost no systemic effect, allowing the use of the technique even in neo-
nates.56 Further details on LDF methodology can be found in the online supplemental 
material.  
 
Clinical applications 
ACh iontophoresis is impaired in disease states such as sleep obstructive apnoea syn-
drome,57 obesity or diabetes, 58,59 heart transplant recipients,60 hypercholesterolaemia or 
hypertension61 even in the absence of macrovascular lesions, and the impaired response 
can be improved after treatment.62 To date, an altered response to ACh iontophoresis 
cannot be used for treatment indication, although it has been shown that many drugs 
that have proved benefit in cardiovascular disease or diabetes can improve the ACh re-
sponse.62–64 Spectral analysis of the LDF signal, standardization of the protocols, and a 
better knowledge of technical issues of iontophoresis are still needed. Nevertheless, 
LDF is an easy and relatively cost-effective technique to approach endothelial function; 
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furthermore, it offers the unique opportunity to test various pathways of the vascular re-
sponse.  
 
Biochemical markers and bioassays  
Several markers have been used to examine different aspects of endothelial cell func-
tions (Figure 3). This review focuses on asymmetrical dimethylarginine (ADMA) and 
oxidized low-density lipoprotein (oxLDL), two key markers of endothelial function. 
ADMA, a product of arginine methylation, represents an endogenous inhibitor of endo-
thelial NO synthase.65 ADMA is, however, not a specific endothelial NO synthase in-
hibitor, but does also inhibit the other NO synthases (iNOS and nNOS). Cross-sectional 
studies have suggested that ADMA plasma concentrations are increased in patients with 
vascular disease, renal failure, or cardiovascular risk factors.66 A large recent cross-
sectional analysis suggested an overall significant, but rather modest inverse association 
between ADMA and endothelial function as measured by flow-dependent vasodila-
tion.67 Studies suggest that increased ADMA plasma levels are independently associated 
with an elevated risk of future cardiovascular events;68,69 however, a recent analysis did 
not observe an association of ADMA plasma levels with the incidence of cardiovascular 
disease.70 Therefore, at present, ADMA measurements may not represent a reliable ‘re-
placement’ of a direct endothelial function measurement, and its association with car-
diovascular prognosis may depend on the patient cohort studied. Oxidized LDL has 
been suggested to contribute importantly to endothelial dysfunction and progression of 
atherosclerosis. Endothelial activation in response to oxidized LDL is likely in particu-
lar mediated by the lectin-like oxidized LDL receptor (LOX-1) present on endothelial 
cells. Oxidized LDL levels are difficult to assess in vivo, and in plasma there are likely 
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only minimally oxidized LDLs present. Several monoclonal antibodies have been used 
to characterize circulating oxidized LDL levels.71 Increased levels of oxidized LDL 
were predictive of future coronary disease events in apparently healthy men,72 while 
plasma oxidized LDL levels predicted the risk of CHD in a large prospective study.73 
However, after adjustment for lipid markers such as apoB and LDL, no independent 
predictive value for plasma oxidized LDL levels was observed. Endothelial bioassays 
can be employed in order to examine the potential effects of therapeutic interventions 
on endothelial cell functions. Isolated highdensity lipoprotein (HDL) from healthy sub-
jects stimulates endothelial cell NO production, whereas HDL isolated from diabetic pa-
tients with low HDL failed to do so,74 suggesting that the endothelial effects of HDL are 
markedly altered in these patients and can be partly restored by niacin therapy. In vitro, 
pathological levels of oxidized LDL are directly cytotoxic to human umbilical vein en-
dothelial cells, and this results in increased release of von Willebrand factor, which is 
associated with a risk of future coronary heart disease.75  
 
Endothelial microparticles 
Microparticles (MPs) are vesicles (100nm to 1 mm diameter) shed from plasma mem-
branes following cell activation or apoptosis.76 MPs of different cellular origins (plate-
lets, leukocytes, red blood cells, endothelial cells, etc.) are found in the plasma of 
healthy subjects and their circulating levels augment in atherothrombotic diseases. Al-
though MPs originating from endothelial cells (EMP) represent a small fraction of the 
overall pool of plasma MPs, increased circulating EMP levels constitute an emerging 
surrogate marker of endothelial dysfunction. If the mechanisms leading to their in-vivo 
formation remain obscure, release of EMPs from cultured cells is increased by tumor 
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necrosis factor a, thrombin, uraemic toxins, and reactive oxygen species. Endothelial 
apoptosis does not appear to be a prerequisite for EMPs generation.77 Interestingly, en-
dothelial NOS uncoupling contributes to EMP release, emphasizing the possible recip-
rocal relationships between EMP and endothelial dysfunction.78 Low shear stress asso-
ciates with increased EMP levels,79 suggesting that physiological shear stress, known to 
contribute to endothelial survival, may limit EMPs release.  
 
Methodology 
Microparticles can be numbered and their cellular origin characterized using different 
methodological approaches based on the identification of cell-surface clusters of differ-
entiation (CD) using specific antibodies and/or the presence of externalized phosphati-
dylserine, which does not discriminate between MP of different cellular origin. Great 
care should be taken to use appropriate controls (e.g. no calcium for annexin V label-
ling) and appropriate isotypes to assess unspecific labelling. EMP may express adhesion 
molecules harboured by mature endothelial cells such as CD54 (ICAM-1), CD106 
(VCAM-1), CD62E (E-selectin), CD62P (P-selectin), or CD31 (PECAM-1). EMP also 
may harbor CD105 (endoglin, also expressed by activated monocyte-macrophages and 
bone marrow cell subsets), CD144 (VE-cadherin), and CD146 (S endo-1, an endothelial 
junctional protein), and they bind von Willebrand factor. Proteomic studies report dif-
ferent EMP phenotypes depending of the vesiculation stimulus. So far, CD144, CD146, 
and CD62E appear to be the most specific markers attesting for the endothelial origin of 
MPs (Figure 4). Methodological details regarding EMP assessment can be found in the 
online supplemental material.  
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Clinical applications 
Circulating EMP levels increase in several cardiovascular and atherothrombotic dis-
eases.80 In end-stage renal disease, EMP plasma levels correlate with arterial stiffness 
and the impairment of flow-mediated dilatation independently of age and blood pres-
sure, whereas such relationship was not observed for other MP populations.81 Similar 
results have been found in diabetes82 and obesity.83 In acute coronary syndromes, in-
creased circulating levels of EMPs correlate with the extent of endothelial dysfunc-
tion.84 EMPs appear as a more robust predictor of the occurrence of myocardial infarc-
tion in diabetic patients, when compared to classical markers of endothelial activation.85 
In addition, plasma EMP levels correlate positively with the extent and severity of 
coronary stenosis at angiography in patients with coronary syndromes.86 Plasma EMP 
levels are also increased in patients with pulmonary hypertension where they predict the 
severity of the disease.87 Increased EMP plasma levels not only reflect endothelial acti-
vation or apoptosis, but they may also increase endothelial dysfunction by impairing 
endothelium-dependent dilation and the endothelial NO pathway.88 
 
Endothelial progenitor cells  
Cardiovascular risk factors damage the endothelial monolayer by inducing endothelial 
cell senescence and apoptosis, leading to endothelial dysfunction. The restoration and 
reconstitution of the damaged endothelial monolayer may be a prerequisite for the pre-
vention of endothelial dysfunction and atherosclerotic lesion formation. Until recently 
endothelial cell repair mechanisms were thought to be mediated by the adjacent endo-
thelial cells. However, adult blood vessels regenerate only moderately in adults under 
physiological conditions. The half-life of an adult endothelial cell has been reported to 
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be 3.1 years.89 A growing body of evidence suggest that circulating, bone mar-
rowderived, endothelial progenitor cells (EPC) play an important role in endothelial cell 
regeneration.90 EPC can be measured from peripheral blood either by direct enumera-
tion using flow cytometry (CD34/KDR, CD34/KDR/CD133 positive EPC) or after cul-
tivation of mononuclear cells (early and late outgrowth EPC).91,92 Methodology Flow 
cytometry. Flow cytometry is used to measure circulating EPC within peripheral blood. 
Most publications use CD34, CD133, and KDR (VEGFR2) as surface markers.91,93 The 
advantages of this technique include its ability to enumerate untouched, naı¨ve cells 
with a defined phenotype and the identification of specific cell populations in multicol-
our fluorescence-activated cell sorting analysis. On the other hand, the definition of 
cells based on surface markers is under heavy debate, while surface markers do not nec-
essarily correlate with cell function. In-vitro assays. In-vitro assays have been widely 
used to identify EPC.94 Two major cell populations have been recently described: early 
and late outgrowth EPC.92 Early outgrowth EPCs are derived from mononuclear cells 
and are cultured using EPC differentiation medium. Regarding late outgrowth EPC, 
there is currently no data available for their role in endothelial function. Reproducibility 
and repeatability severely depend on the method used. Cell enumeration of rare cells us-
ing fluorescence-activated cell sorting analysis is highly dependent on the protocol used 
and the experience of investigator. A standardized protocol with clinical evaluation has 
been published.91 Further details on standardization issues can be found in the online 
supplemental material. 
 
Clinical applications 
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Various publications have demonstrated a correlation between EPC, severity of endo-
thelial dysfunction measured either invasively or non-invasively, and outcomes.93,95,96 
However, others97,98 have failed to describe a correlation between EPC and endothelial 
function. All published results are descriptive and no clinical trials are available demon-
strating that therapeutic interventions of circulating EPC numbers can improve endothe-
lial function. First hints that stem and progenitor cells may positively influence impaired 
endothelial function comes from a substudy of the REPAIR-AMI trial demonstrating 
restoration of microvascular function of the infarct-related artery after bone marrow 
stem cell transfusion.99 Mobilization therapy using drugs and substances with effects on 
the number of circulating EPC has shown an improvement of endothelial function.100 A 
clear causal role has not been established yet. Currently, there is no strong evidence for 
a clear dependency of EPC numbers (within circulating blood or subcultured EPC) with 
the extent of endothelial dysfunction. Additionally, the role of EPC as a guide to treat-
ment has not been established yet. In the clinical setting, more and larger clinical studies 
evaluating EPC and its correlation with endothelial function are needed. Furthermore, 
large clinical trials are warranted with an interventional approach to enhance the number 
of circulating EPC in order to establish the role of EPC in improving endothelial func-
tion.  
 
 
Endothelial glycocalyx 
The glycocalyx forms a gel-like layer covering the endothelial lining, shielding endo-
thelial cells from direct contact with circulating blood cells (Figure 5). This strategic 
position already implies its potential role in several crucial balances at the level of the 
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vessel wall, including the vasoconstrictor–vasodilator, the pro- and anticoagulant, the 
pro- and anti-inflammatory, as well as the pro- and antioxidative balance. Under physio-
logical conditions, the endothelial glycocalyx preserves the integrity of the vessel wall. 
It serves as an inert barrier that precludes direct ‘endothelial’ contact and creates a se-
lectively permeable structure contributing to the generation of the osmotic pressure gra-
dient across the vessel wall. The glycocalyx serves as an active reservoir containing ma-
jor enzymatic systems and their cofactors [lipoprotein lipase (LPL), extracellular super-
oxide dismutase (ec-SOD), antithrombin III (AT III), anticoagulant heparansulphates 
and thrombomodulin].101 It has an important role as mechano-transductor, transferring 
shear stress into shear-dependent endothelial responses; this leads to NO release.102 
Damage to the endothelial glycocalyx is associated with influx of lipoproteins, leakage 
of macromolecules, and adhesion of circulating cells to the endothelium. Concomi-
tantly, loss of glycocalyx may contribute to an imbalance in enzymatic systems such as 
coagulation and antioxidant defence as well as an impaired NO release.103 As glycosa-
minoglycan (GAG) synthesis is under direct negative feedback of inflammatory and 
oxidative stimuli,104 this indicates that a pro-atherogenic environment has a direct im-
pact on both GAG composition as well as glycocalyx dimension. In turn, both a de-
creased rate and aberrant composition of GAG synthesis may contribute to vascular in-
flammation and vascular dysfunction. 
 
Methodology 
Glycocalyx measurements can be performed using invasive or non-invasive tech-
niques. In the first technique, systemic glycocalyx volume is measured using the glyco-
calyx permeable tracer Dextran 40 versus a glycocalyx impermeable tracer, fluorescein-
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labelled erythrocytes. The calculated difference between the two intravascular volumes 
that these tracers occupy renders a reasonable estimation of whole-body glycocalyx 
volume.105 However, the invasive nature and the timeconsuming preparations precludes 
its use in larger cohorts. Moreover, it is not clear whether this method considers the en-
dothelial glycocalyx as uniformly distributed throughout the vasculature. Nevertheless, 
this technique may be of use in order to obtain a first indication of systemic glycocalyx 
dimensions in humans. The second, non-invasive technique uses a semiautomated imag-
ing method to estimate glycocalyx thickness by OPS (Orthogonal Polarization Spectral 
imaging) or SDF (Sideview Darkfield imaging) at the superficial microvasculature. 
Glycocalyx limits the proximity of erythrocytes to the capillary endothelial cells; this 
imaging method uses the erythrocyte– endothelium gap of the capillaries in the image to 
quantify glycocalyx thickness.  
 
Clinical applications  
Controlled inflammatory challenges lead to instantaneous shedding of glycocalyx 
constituents and leukocyte activation in conjunction with a profound decrease in glyco-
calyx dimension. Pre-treatment with etanercept, a soluble tumour necrosis factor a re-
ceptor, prevented leukocyte activation as well as shedding of glycocalyx compounds.106 
Acute hyperglycaemia results in a perturbation of the endothelial glycocalyx with a 
concomitant increase in vascular permeability,105,107 and changes in glycocalyx bio-
chemistry are associated with carotid intima media thickness, an established marker of 
cardiovascular disease, in type 1 diabetes mellitus patients.107 In patients with familial 
hypercholesterolemia, an inverse relationship between plasma LDL cholesterol levels 
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and glycocalyx dimensions exists, whereas cholesterol- lowering treatment resulted in 
partial recovery of glycocalyx.108 
 
Perspectives 
The advent of multiple methods allows for a thorough approach to endothelial func-
tion. A comparison between these methods should take into account the pathophysi-
ological relevance, validation and reproducibility, ability to predict events in diverse pa-
tient groups, ease of use, cost-effectiveness, and, ultimately, the ability to outperform 
traditional risk assessment tools.109 The aforementioned techniques have a firm theoreti-
cal basis and address different facets of endothelial physiology. Older methods have 
been largely validated in multiple studies/subpopulations and proven useful in the re-
classification of risk. Protocols have been largely standardized and this has resulted in 
reproducible measurements. However, a consensus has yet to be reached for most of the 
ex-vivo methods. All of the techniques are acceptable to the patient; learning curves and 
the necessity for special equipment may hamper the adoption of the most elaborate 
techniques in everyday clinical practice. Finally, the incremental predictive value has 
been established for all but the most recently developed ones. While no single method 
should be seen as an overall winner, it is nevertheless clear that they all add up to better 
prevention and, eventually, reversal of cardiovascular disease. Evaluation of endothelial 
function appears as an appealing adjunct for risk stratification. However, before its 
clinical implementation, it is essential that studies will address highly relevant ques-
tions, including which groups will benefit the most from such techniques and whether 
any clinical benefit from a specific therapeutic strategy is mediated through an im-
provement in endothelial function. 
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FIGURES 
 
 
 
 
Figure 1:  Schematic of a Doppler guidewire including an infusion catheter and a 12 
MHz Doppler wire. The coaxial position of the wire in the vessel lumen can be appreci-
ated. Also shown are two 1 cm-vessel segments where changes in vessel diameter are 
measured proximal and distal to the injection site of the vasodilator agent. Source: E-
xerc Sport Sci Rev © American College of Sports Medicine 
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Figure 2: Flow mediated dilatatation. The top figure illustrates the optimal set-up for 
FMD measurements. The bottom figures demonstrate brachial artery in a longitudinal 
section (A) and the output using the automated analysis software (Brachial Analyser) 
(B).  
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Figure 3: Schema for PWA assessment of endothelial function. SLB = salbutamol 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Typical recordings from the EndoPat. Estimation of PAT ratio after correc-
tion of the reactive hyperemia index for the control arm. Probe 1 corresponds to the oc-
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cluded arm and probe 2 to the control arm. The blue colored interval corresponds to the 
duration of occlusion in the test arm. 
 
Figure 5: Types of investigation with Laser Doppler flowmetry. 
 
 
 
Figure 6: Biomarkers for endothelial functions 
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Figure 7: Representative flow cytometry experiment aiming at identifying circulating 
endothelial CD144+ MPs in acute myocardial infarction. A: identification of fluorescent 
synthetic beads within the MP size range (Blue= 0.5 µm; Green= 0.8 µm and Red= 3 
µm in diameter). B: forward scatter (FS) vs. side scatter (SS) dot plot representation 
showing MPs (black) and synthetic beads. C: Representative flow cytometry fluores-
cence histogram showing the presence of CD144 (VE-cadherin) on circulating MPs 
(purple line). The black line corresponds to negative control (isotypic IgGs). Platelet-
free plasma was obtained as indicated above and exposed to anti-VE-cadherin mono-
clonal antibody coupled to phycoerythrin (PE; purple line) or its isotypic control (black 
line). D: forward scatter (FS) vs. side scatter (SS) dot plot representation showing endo-
thelial CD144+MPs (purple dots) in the platelet-free plasma of a patients with acute 
myocardial infarction. 
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Figure 8: Electron microscopy image of coronary endothelial glycocalyx (courtesy 
of B. van den Berg, Maastricht University).  
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TABLES 
 
Molecule Function Synonym Distribution 
CD14 Receptor/signaling LPS receptor Monocytes, macrophages and 
neutrophils 
 
CD31 Adhesion PECAM-1 Very widely distributed 
CD34 Adhesion (precise 
function unclear) 
 Leukocytes at various stages 
of differentiation, especially 
haemopoietic or endothelial 
progenitors. 
Also on numerous neoplastic 
cells. 
CD45 Signaling Leukocyte common 
antigen 
‘Mature’ and neoplastic leu-
kocytes 
 
CD69E Adhesion E-selectin Endothelial cells 
CD105 Signaling TFG-β recep-
tor/endoglin 
Endothelial cells, 
activated monocytes, 
pre-B lymphocytes 
CD133 Unclear Promin-1 Haematopoietic stem cells, 
endothelial progenitor cells, 
some neuronal cells 
CD144 Adhesion and sig- VE-Cadherin Endothelial cells 
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naling 
CD146 Adhesion Mel-CAM/MUC-18 Mature endothelial cells, 
T lymphocytes, 
some neoplastic cells. 
CD202b Signaling Tie-2 (angiopoietin 
receptor) 
Endothelial cells 
CD309 Signaling VEGFR2/KDR/Flk-1 Endothelial cells 
 
Table 1 Cell surface molecules used to define endotheliod cells in vivo and in vitro. 
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Name of cell Abbreviation 
Angioblast - 
Blood outgrowth endothelial cell# BOEC 
Circulating angioblast - 
Circulating angiogenic cell CAC* 
Circulating endothelial cell CEC 
Circulating endothelial progenitor cell CEPC 
Endothelial cell colony forming unit CFU-EC*# 
Culture modified mononuclear cells CMMC* 
Circulating progenitor cell CPC 
Endothelial cell EC*# 
Endothelial-like cell ELC 
Endothelial colony forming cell ECFC 
Endothelial progenitor cell EPC*# 
Endothelial outgrowth cell EOC 
Haemopoietic precursor cell HPC 
Haemopoietic stem cell HSC 
Multipotent adult progenitor cell MAPC 
 
Table 2 Endotheliod cells. All of these cells are defined by different but often overlap-
ping markers in vivo and in vitro. *EC-like cells, #EOCs 
 
